ANCA相关性血管炎患者利妥昔单抗维持治疗期间的复发与严重不良事件:一项多中心回顾性研究
该多中心回顾性研究纳入101例接受利妥昔单抗维持治疗的GPA/MPA患者,中位随访3个周期共294.5患者年,24例(24%)复发,发生率为10.2/100患者年,其中57%为大复发。肾脏受累、RTX联合CYC诱导及更早达到完全缓解与较低复发风险相关;严重感染率为5.8/100患者年,COVID-19相关住院率为3.7/100患者年。
要点
- RTX维持治疗期间约1/4患者复发,复发率10.2/100患者年,57%为大复发。
- 肾脏受累、RTX联合CYC诱导及更早达完全缓解与较低复发风险相关。
- 严重感染率5.8/100患者年,COVID-19相关住院率3.7/100患者年。
核心结论
- 在真实世界中,RTX维持治疗期间约1/4患者发生复发。
- 肾脏受累、RTX联合CYC诱导及更早达到完全缓解与较低复发风险相关。
- 严重感染率与既往报告一致,但观察到COVID-19相关住院率升高。
研究设计与样本
- 多中心回顾性队列研究,纳入新诊断或复发性GPA/MPA患者101例。
- 纳入标准为接受RTX维持治疗(≥1个RTX周期,随访≥6个月)且经诱导方案达到完全缓解(BVAS第3版=0且泼尼松龙≤7.5 mg/天)。
- 采用Kaplan-Meier法估计发生率与无复发生存率,Cox回归分析复发时间相关因素。
主要发现
- 中位年龄63岁,女性48%,GPA 69%,新诊断53%;随访294.5患者年,中位3个RTX周期。
- 24例患者发生30次复发(24%,发生率10.2/100患者年),其中57%为大复发。
- 肾脏受累与复发风险降低相关(aHR 0.20;95% CI 0.06-0.74,P=0.016)。
- RTX联合CYC诱导较RTX单药诱导与复发风险降低相关(aHR 0.02;95% CI 0.001-0.43,P=0.012)。
- 更短时间达到完全缓解与复发风险降低相关(aHR 1.07;95% CI 1.01-1.14,P=0.023)。
关键数值与推荐
- 严重感染17例(发生率5.8/100患者年)。
- COVID-19相关住院11例(发生率3.7/100患者年)。
- 恶性肿瘤4例(发生率1.4/100患者年)。
- 心血管事件6例(发生率2/100患者年)。
- 死亡10例(发生率3.4/100患者年)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: There are limited real-life data regarding the efficacy and safety of rituximab (RTX) as a remission maintenance agent in microscopic polyangiitis (MPA) and granulomatosis-with-polyangiitis (GPA). We aimed to estimate the incidence and risk factors for relapses, as well for serious adverse events (SAEs) in MPA/GPA patients during RTX maintenance. METHODS: A retrospective cohort of newly diagnosed/relapsing GPA/MPA patients who received RTX maintenance (≥1 RTX cycle, ≥6 months follow-up) following complete remission (BVAS version-3 = 0 plus prednisolone ≤7.5 mg/day) with induction regimens. SAEs included serious infections, COronaVIrus-Disease 2019 (COVID-19)-associated hospitalizations, deaths, cardiovascular events, malignancies and hypogammaglobulinemia. The incidence rates (IRs) and relapse-free survival were estimated through Kaplan-Meier plots. Cox regression was conducted to investigate factors associated with the time-to-relapse. RESULTS: A total of 101 patients were included: 48% females, 69% GPA, 53% newly diagnosed, median age 63 years. During follow-up (294.5 patient-years, median: 3 RTX cycles), 30 relapses (57% major) occurred among 24 patients (24%, IR 10.2/100 patient-years). Kidney involvement (adjusted hazard ratio/aHR: 0.20; 95% CI: 0.06-0.74, P = 0.016), prior induction with RTX plus CYC (vs RTX monotherapy: aHR = 0.02; 95% CI: 0.001-0.43, P = 0.012) and shorter time interval until complete remission (aHR = 1.07; 95% CI: 1.01-1.14, P = 0.023) were associated with decreased relapse risk. We recorded 17 serious infections (IR 5.8/100 patient-years), 11 COVID-19-associated hospitalizations (IR 3.7/100 patient-years), 4 malignancies (IR 1.4/100 patient-years), 6 cardiovascular events (IR 2/100 patient-years) and 10 deaths (IR 3.4/100 patient-years). CONCLUSION: In this real-world study, relapses during RTX maintenance occurred in approximately 1 out of 4 patients. Kidney involvement, induction with RTX plus CYC, and earlier achievement of complete remission were associated with lower relapse risk. The serious infections rate was consistent with previous reports, whereas an increased rate of COVID-19-associated hospitalizations was observed.
引用
- Gialouri CG, Chalkia A, Koutsianas C, et al. Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study. Rheumatology (Oxford). 2025. PMID: 39107924. doi:10.1093/rheumatology/keae409
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。